Biotechnology

ATYR Pharma

ATYR Pharma released FY2025 annual earnings on March 5 (EST), actual revenue USD 190 K (forecast USD 117 K), actual EPS USD -0.7999 (forecast USD -0.8162)

ATYR Pharma released FY2025 Q4 earnings on March 5 (EST), actual revenue USD 0 (forecast USD 20 K), actual EPS USD -0.1424 (forecast USD -0.175)

ATYR Pharma released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 190K (forecast USD 0), actual EPS USD -0.2649 (forecast USD -0.1881)

ATYR Pharma released FY2025 9 Months earnings on November 6, 2025 (EST), actual revenue USD 190K, actual EPS USD -0.6537

aTyr Pharma Presents Additional Findings of the Phase 3 EFZO-FIT™ Study of Efzofitimod at the 2025 European Respiratory Society Congress

ATYR PHARMA Announces EFZO-FIT™ Study Misses Primary Endpoint

Cantor Fitzgerald Reiterates 'Outperform' Rating on aTyr Pharma Stock

ATYR Pharma released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2167 (forecast USD -0.1827)

ATYR Pharma released FY2025 Semi-Annual earnings on August 7 (EST), actual revenue USD 0, actual EPS USD -0.3896

aTyr Pharma to Release 2025 Q2 Earnings Report

Wells Fargo Maintains aTyr Pharma Rating and Raises Target Price

Bank of America Acquires Atyr Pharma Shares

HC Wainwright Maintains Buy Rating on ATYR Pharma

Dimensional Fund Advisors LP Invests in Atyr PHARMA INC

ATYR Pharma Announces Inducement Grant Under NASDAQ Rule 5635(C)(4)

ATYR Pharma released FY2025 Q1 earnings on May 7, 2025 (EST), with actual revenue USD 0 (forecast USD 0) and actual EPS USD -0.172 (forecast USD -0.19)

Atyr PHARMA INC Stock Short Interest Increases

ATYR Pharma released FY2024 annual earnings on March 13 After-Market (EST), actual revenue 235 K USD (forecast 165.73 K USD), actual EPS -0.8621 USD (forecast -0.9109 USD)

ATYR Pharma released FY2024 Q4 earnings on March 13 After-Market EST, actual revenue 0 USD (forecast 0 USD), actual EPS -0.1809 USD (forecast -0.226 USD)

ATYR Pharma to Release FY2024 Earnings on March 13, After-Market EST; Forecasted Revenue 165.73 K USD, EPS -0.9109 USD

Paranovus ENT Tech

Robin Energy - WI

ENvue Medical

Fundrise Innovation Fund LLC

CVD Equipment

T-REX 2X Inverse CRCL Daily Target ETF

AleAnna

Swarmer

Sol-Gel Tech

DRUGS MADE IN AMERICA ACQ II CORP ORD USD0.0001 (SUBS/RTS) 16/09/2030

Kiniksa Pharmaceuticals

MiMedx

Rigel制藥

CapForce Inc.

OpGen

福泰制藥

Argenx

阿里拉姆制藥

百濟神州

Natera

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

ATYR Pharma(ATYR.US)

ATYR Pharma Stock Performance Chart